Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.
暂无分享,去创建一个
Hideki Matsui | Shoji Fukumoto | Midori Ono | Takashi Motoyaji | Tomoaki Hasui | Toshimasa Tanaka | H. Matsui | N. Habuka | S. Sogabe | Satoshi Sogabe | Noriyuki Habuka | Toshimasa Tanaka | Tomoaki Hasui | Nobuyuki Matsunaga | Taiichi Ora | Norio Ohyabu | Nobuhiro Nishigaki | Yoshimi Imura | Yumiko Igata | Christopher S Siedem | Tony P Tang | Cassandra Gauthier | Lisa A De Meese | Steven A Boyd | Norio Ohyabu | C. Siedem | Nobuhiro Nishigaki | S. Fukumoto | M. Ono | T. P. Tang | Cassandra Gauthier | S. Boyd | Y. Imura | Takashi Motoyaji | N. Matsunaga | Y. Igata | Taiichi Ora | Yumiko Igata
[1] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[2] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[3] Jessica Huyet,et al. Structural Basis of Spirolactone Recognition by the Mineralocorticoid Receptor , 2007, Molecular Pharmacology.
[4] Kagawa Cm. Blocking the renal electrolyte effects of mineralocorticoids with an orally active steroidal spirolactone. , 1960 .
[5] Koichi Hayashi,et al. Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy , 2003, Hypertension.
[6] P. Raskin,et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. , 2009, Journal of the American Society of Nephrology : JASN.
[7] N. Chapman,et al. Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension , 2007, Hypertension.
[8] K. Weber,et al. Aldosterone in Congestive Heart Failure , 2004 .
[9] Xu Shen,et al. Synthesis, modification, and evaluation of (R)-de-O-methyllasiodiplodin and analogs as nonsteroidal antagonists of mineralocorticoid receptor. , 2011, Bioorganic & medicinal chemistry letters.
[10] A. Vagin,et al. MOLREP: an Automated Program for Molecular Replacement , 1997 .
[11] C. Kagawa. Blocking the renal electrolyte effects of mineralocorticoids with an orally active steroidal spirolactone. , 1960, Endocrinology.
[12] W L Miller,et al. Molecular biology of mineralocorticoid metabolism. , 1996, Annual review of nutrition.
[13] K. Fujita,et al. SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity. , 2011, Journal of pharmacological sciences.
[14] F. Kajiya,et al. Involvement of Aldosterone and Mineralocorticoid Receptors in Rat Mesangial Cell Proliferation and Deformability , 2005, Hypertension.
[15] Timothy M Willson,et al. A Ligand-mediated Hydrogen Bond Network Required for the Activation of the Mineralocorticoid Receptor*[boxs] , 2005, Journal of Biological Chemistry.
[16] Alexander Hillisch,et al. A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule* , 2010, The Journal of Biological Chemistry.
[17] Azra Mahmud,et al. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? , 2005, American journal of hypertension.
[18] G. Stephenson,et al. (S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor. , 2007, Journal of medicinal chemistry.
[19] D. Cusi,et al. Mechanisms of Disease: the role of aldosterone in kidney damage and clinical benefits of its blockade , 2007, Nature Clinical Practice Nephrology.
[20] M. J. Meyers,et al. Non-steroidal mineralocorticoid receptor antagonists , 2007 .
[21] Z. Otwinowski,et al. Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[22] M. Young,et al. Cardiac steroidogenesis in the normal and failing heart. , 2001, The Journal of clinical endocrinology and metabolism.
[23] J. Ménard,et al. Antialdosterones: incidence and prevention of sexual side effects. , 1989, Journal of steroid biochemistry.
[24] D. Sica. Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis , 2005, Heart Failure Reviews.
[25] B. Pitt,et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .
[26] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[27] B. Pitt,et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .
[28] Henry Krum,et al. A Comparison of the Aldosterone‐blocking Agents Eplerenone and Spironolactone , 2008, Clinical cardiology.
[29] M. Heron,et al. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. , 2010, Journal of medicinal chemistry.
[30] J. Ménard,et al. Efficacy and tolerance of spironolactone in essential hypertension. , 1987, The American journal of cardiology.
[31] Claudine Mayer,et al. Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension , 2005, Nature Structural &Molecular Biology.
[32] B. Roniker,et al. Eplerenone: a selective aldosterone receptor antagonist (SARA). , 2006, Cardiovascular drug reviews.
[33] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[34] Vincent B. Chen,et al. Correspondence e-mail: , 2000 .